超基因医药

US · RARE #3012 按市值排名上市于 1970

14.54 -0.63 -4.15%

实时 - 追踪5344个代码 - 心跳于329秒前 · 2026-10-16 19:56

✦ 量化股权信号计算方式说明

增持

机构持股总比例上升了0.1个百分点。

机构持股

机构持股比例: 110.53% +0.14pp
机构数量: 385
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund66.69%

Hedge Fund32.34%

Public Company4.63%

VC/PE Fund4.16%

Individual/Insider3.60%

Private Company1.56%

Insurance Company0.46%

Government Pension Fund0.34%

Family Office/Trust0.26%

主要股东截至 2026-06-30

BlackRock 10.84% · 10.65M 股

RTW Investments, LP 7.93% · 7.80M 股

Vanguard Portfolio Management, LLC 6.91% · 6.79M 股

AQR Capital Management 6.65% · 6.53M 股

State Street Global Advisors 6.27% · 6.16M 股

Vanguard Capital Management, LLC 5.05% · 4.97M 股

Two Sigma Investments, LP 3.68% · 3.62M 股

Sands Capital Management, LLC 3.21% · 3.16M 股

Jacobs Levy Equity Management Inc 2.99% · 2.94M 股

Frontier Capital Management 2.90% · 2.85M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 30次买入 · 20次卖出

姓名	职务	持股比例
Emil Kakkis	Chief Executive Officer	2.80%
Thomas Kassberg	Chief Business Officer & Executive VP	0.24%
Dennis Huang	Chief Technical Operations Officer & Gene Therapy Operations and Executive VP	0.10%
John Pinion	Chief Quality Operations Officer & Executive VP of Translational Sciences	0.09%
Erik Harris	Executive Vice President	0.06%
Eric Crombez	Chief Medical Officer & Executive VP	0.05%
Karah Parschauer	Chief Legal Officer & Executive VP	0.04%
Daniel Welch	Independent Non-Executive Chairperson	0.03%
Michael Narachi	Independent Director	0.03%
Theodore Huizenga	Senior VP, Corporate Controller & Principal Accounting Officer	0.03%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-14	Theodore Huizenga	Senior VP, Corporate Controller & Principal Accounting Officer	Open Market Disposition	-1,283	$13.57
2026-09-02	Theodore Huizenga	Senior VP, Corporate Controller & Principal Accounting Officer	Open Market Disposition	-161	$13.99
2026-08-02	Howard Horn	Chief Financial Officer	Open Market Disposition	-4,696	$24.92
2026-08-02	Karah Parschauer	Chief Legal Officer & Executive VP	Open Market Disposition	-1,900	$24.92
2026-06-30	Howard Horn	Chief Financial Officer	Open Market Disposition	-4,698	$33.13
2026-06-14	Corazon Sanders	Independent Director	Open Market Disposition	-2,000	$25.05
2026-06-14	Karah Parschauer	Chief Legal Officer & Executive VP	Open Market Disposition	-1,899	$24.62
2026-05-31	Howard Horn	Chief Financial Officer	Open Market Disposition	-4,653	$23.77
2026-05-17	Shehnaaz Suliman	Independent Director	Open Market Disposition	-5,740	$25.12
2026-05-13	Daniel Welch	Independent Non-Executive Chairperson	Other Acquisition	+7,751	--
2026-05-13	Daniel Welch	Independent Non-Executive Chairperson	Other Derivative Acquisition	+14,058	$25.80
2026-05-13	Matthew Fust	Independent Director	Other Acquisition	+7,751	--
2026-05-13	Matthew Fust	Independent Director	Other Derivative Acquisition	+14,058	$25.80
2026-05-13	Shehnaaz Suliman	Independent Director	Other Acquisition	+7,751	--
2026-05-13	Shehnaaz Suliman	Independent Director	Other Derivative Acquisition	+14,058	$25.80
2026-05-13	Deborah Dunsire	Independent Director	Other Acquisition	+7,751	--
2026-05-13	Deborah Dunsire	Independent Director	Other Derivative Acquisition	+14,058	$25.80
2026-05-13	Corazon Sanders	Independent Director	Other Acquisition	+7,751	--
2026-05-13	Corazon Sanders	Independent Director	Other Derivative Acquisition	+14,058	$25.80
2026-05-13	Michael Narachi	Independent Director	Other Acquisition	+7,751	--

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:56:13 · 仅供参考，不构成投资建议，也未考虑您的具体情况。